Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: The experience of a single center in Brazil

International Journal of Hematology

Volumn 84, Issue 4, 2006, Pages 337-342

  Tanaka, Paula Yurie ^a,b   Pracchia, Luis Fernando ^a   Calore, Edenilson Eduardo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE INFECTOLOGIA EMÍLIO RIBAS   (Brazil)

Author keywords

AIDS; Brazil; HIV; Non Hodgkin's lymphoma; Retrospective study

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EFAVIRENZ; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VINCRISTINE; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BRAZIL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE; ADOLESCENT; B CELL LYMPHOMA; MIDDLE AGED; MORTALITY; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAZIL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 34247210986     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.06116     Document Type: Article

References (21)

1. Centers for Diseases Control, Department of Health and Human Services. Revision of the case definition of acquired immunodeficiency syndrome for national reporting - United States. Ann Intern Med. 1985;103:402-403.
2. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol. 2000;27:390-401.
3. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991;337:805-809.
4. Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol. 2000;27:442-453.
5. Levine AM. AIDS related lymphoma. Blood. 1992;80:8-20.
6. Hoffmann C, Wolf E, Fatkenheuer G. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003;17:1521-1529.
7. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet. 2000;356:291-296.
8. Biggar RJ. AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology (Williston Park). 2001;15:439-448.
9. Bastos FI, Kerrigan D, Malta M, Carneiro-da-Cunha C, Strathdee SA. Treatment for HIV/AIDS in Brazil: strengths, challenges, and opportunities for operations research. AIDScience [serial online]. 2001;1(no. 15). Published November 27, 2001. Available at: http://www.aidscience.org/Articles/ aidscience012.pdf. Accessed August 10, 2006.
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma: NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
11. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood. 1994;83:1165-1173.
12. Kaplan LD, Straus DJ, Testa MA, et al, for the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med. 1997;336:1641-1648.
13. Ratner L, Ambinder R, Levine A, et al, for the AIDS Malignancy Consortium. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171-2178.
14. Sparano JA, Lee S, Chen M, et al. Phase II trial of infusional cyclophosphamide, doxorubicin and etoposide (CDE) in HIV associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21:A39. Abstract 120.
15. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653-4659.
16. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107:3832-3840.
17. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol. 1999;26(suppl 14):79-87.
18. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
19. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538-1543.
20. Dunleavy K, Wilson W. The case for rituximab in AIDS-related lymphoma. Blood. 2006;107:3014-3015.
21. Kaplan LD. Rituximab, chemotherapy, and HIV-associated lymphoma. Blood. 2006;107:3015.